Unlock Migraine Relief: The Power of Advanced Pharmaceutical Intermediates
Discover the critical Rimegepant intermediate for cutting-edge migraine therapy development.
Get a Quote & SampleProduct Core Value
![(6S,9R)-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-9-[[Tris(1-Methylethyl)Silyl]Oxy]-5H-Cyclohepta[b]](https://www.nbinno.com/webimg/gemini_6880d6e7cba4b_1753274087.png)
(6S,9R)-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-9-[[Tris(1-Methylethyl)Silyl]Oxy]-5H-Cyclohepta[b]Pyridin-5-One
This advanced pharmaceutical intermediate is pivotal in the synthesis of Rimegepant, a groundbreaking medication designed to target and inhibit the CGRP receptor, a key mediator in migraines. Its precise chemical structure and high purity are essential for the efficient and successful development of novel migraine treatments, making it a cornerstone in modern pharmaceutical research.
- Facilitating Rimegepant intermediate synthesis, this compound is crucial for producing advanced therapeutic agents.
- As a vital pharmaceutical intermediate for migraine drugs, it supports the creation of effective treatments.
- The specific CAS 1190363-46-2 intermediate designation ensures traceability and quality control in drug development.
- Its role in CGRP receptor antagonist synthesis highlights its importance in developing targeted therapies for neurological conditions.
Key Product Advantages
Purity and Consistency
Ensuring high purity levels for this critical pharmaceutical intermediate for migraine drugs guarantees reliable outcomes in complex synthesis pathways.
Enabling Drug Development
As a key component in Rimegepant intermediate synthesis, it accelerates the research and development of new anti-migraine therapies.
Specialized Chemical Properties
The unique chemical structure of the CAS 1190363-46-2 intermediate makes it indispensable for creating targeted CGRP receptor antagonists.
Key Applications
Migraine Treatment Advancement
This compound is integral to the Rimegepant intermediate synthesis, directly contributing to the development of novel migraine treatments.
Pharmaceutical Research
Researchers rely on this specific CAS 1190363-46-2 intermediate for exploring new therapeutic avenues in neurology and beyond.
Custom Synthesis Projects
It serves as a high-value building block for custom synthesis of Rimegepant intermediates and related complex molecules.
CGRP Receptor Antagonist Development
Essential for CGRP receptor antagonist synthesis, this intermediate supports the creation of targeted therapies for severe headaches.